Vale+ Program for Coronavirus Prevention

Overseen By Cesar L Pinzon-Gomez

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: The University of Texas Health Science Center, Houston

Disqualifiers: Not hired at corner, COVID-19 symptoms

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

300 Participants Needed

Trial Summary

Do I need to stop my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications.

How is the Vale+ Program for Coronavirus Prevention treatment different from other COVID-19 treatments?

The Vale+ Program for Coronavirus Prevention, involving COVID-19 Group Problem Solving, is unique because it focuses on a collaborative approach to problem-solving rather than traditional medical treatments. This method emphasizes group strategies and community engagement to prevent COVID-19, which is different from standard drug-based or vaccine treatments. ^{1 2 3 4 5}

What is the purpose of this trial?

The purpose of this study is to determine the cultural, socioeconomic, inter/personal and work-related factors that influence COVID 19 mitigation practices including social distancing, hand-washing and Personal protective equipment (PPE) use, to adapt, implement, and test Vale+Tú Salud in a cluster randomized trial to assess the extent to which LDL report increased adherence with COVID 19 mitigation practices 1 month post intervention and to promote Vale+Tú Salud just-in-time results and increase its capacity to rapidly disseminate findings among groups that serve LDL and other Latino immigrants.

Research Team

Maria E Fernandez-Esquer, PhD

Principal Investigator

The University of Texas Health Science Center, Houston

Eligibility Criteria

This trial is for Latino Day Laborers (LDL) and focuses on understanding how cultural, social, and work factors affect COVID-19 safety practices. Participants will help test a program aimed at improving adherence to measures like social distancing and PPE use.

Inclusion Criteria

Self-identify as Hispanic or Latino

Be present at the corner for the purposes of looking for work

Exclusion Criteria

Have not been previously hired to work at a corner

I have had COVID-19 symptoms in the last 2 days.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Implementation and testing of Vale+Tú Salud to assess adherence to COVID-19 mitigation practices

1 month

Follow-up

Participants are monitored for adherence to COVID-19 mitigation practices post-intervention

4 weeks

Treatment Details

Interventions

• Booster session
• COVID-19 Group Problem Solving
• Standard of Care

Trial Overview The study tests 'Vale+Tú Salud', an adapted program for LDLs to prevent COVID-19 spread. It includes group problem-solving sessions, standard care advice, and booster sessions to reinforce behaviors.

Participant Groups

Group I: COVID-19 Group Problem Solving and booster call Experimental Treatment 3 Interventions

Group II: Standard of Care Active Control 1 Intervention

Who Is Running the Clinical Trial?

The University of Texas Health Science Center, Houston

Lead Sponsor

Trials

974

Recruited

361,000+

National Institute on Minority Health and Health Disparities (NIMHD)

Collaborator

Trials

473

Recruited

1,374,000+

References

1. Switzerland pubmed.ncbi.nlm.nih.gov

Group Testing for SARS-CoV-2 Allows for Up to 10-Fold Efficiency Increase Across Realistic Scenarios and Testing Strategies. [2021]

2. England pubmed.ncbi.nlm.nih.gov

Pilot study of an occupational healthcare program to assess the SARS-CoV-2 infection and immune status of employees in a large pharmaceutical company. [2021]

3. Switzerland pubmed.ncbi.nlm.nih.gov

Optimal Allocation of COVID-19 Test Kits Among Accredited Testing Centers in the Philippines. [2022]

4. England pubmed.ncbi.nlm.nih.gov

A discussion on implementing pooling detection tests of novel coronavirus (SARS-CoV-2) for a large population. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

ANERGY TO SYNERGY-THE ENERGY FUELING THE RXCOVEA FRAMEWORK. [2021]